INTRODUCTION

The increasing menace of the post-antibiotic era has incited research and development of new antibacterial agents, however, limited success has been achieved in overall synthesis and discovery of novel antibiotics with unique mechanisms of action. This can be further corroborated by the fact that only 8 new antibacterial agents were Food and Drug Administration (FDA) approved from 2010 to 2018, all of which were derived from well-known drug classes. In the current scenario of antibacterial development, drugs targeting lethal multidrug-resistant (MDR) Gram-negative bacteria seems promising, in comparison to more common MDR Gram-positive bacteria and/or organisms causing sexually transmitted infections. The later subgroup includes

ABSTRACT

The advent and spread of antimicrobial resistance has led to a global public health emergency necessitating development of new antimicrobial drugs. Community acquired bacterial pneumonia (CABP) contributes a major portion of societal burden with increasing morbidity due to evolution of drug resistant strains. Lefamulin is a novel pleuromutilin antibiotic with unique mechanism of action through inhibition of protein synthesis by binding to the peptidyl transferase center of the 50s bacterial ribosome. The drug displays activity against Gram positive and atypical organisms associated with CABP (i.e., Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, Legionella pneumophila, and Chlamydia pneumoniae), with an expanded Gram-positive spectrum including Staphylococcus aureus (i.e., methicillin-resistant, vancomycin-intermediate, and heterogeneous strains). Lefamulin is available in both intravenous (IV) and per oral (PO) formulation, exhibits high nonlinear plasma protein binding with low unbound concentrations, higher concentrations in lung epithelial lining fluid (ELF) than in plasma, and a half-life of approximately 10 hour. The recommended IV dose is 150 mg twice daily over 1 hour or a PO dose of 600 mg twice daily. Most common adverse drug reactions injection site reactions, hepatic enzyme elevation, nausea, diarrhoea, hypokalemia, insomnia, and headache. Clinical trials for lefamulin have been positive and Phase 3 data suggest similar efficacy when compared to moxifloxacin with or without linezolid in CABP. Also, the documented resistance and cross-resistance with other Gram-positive antibacterials remains low. With Nabrivia Pharmaceuticals having already received US FDA approval in August 2019, lefamulin may soon be a new addition to the mounting armoury of drugs against CABP.

Keywords: Lefamulin, Pleuromutilin, CABP, Multidrug resistance, Gram positive pathogens

Lefamulin: novel pleuromutilin drug for community acquired bacterial pneumonia

A. P. Dubey1, Sachin Maggo2*, Awanish Karan3, N. K. Singh4, Sreya Bhaskaran5

1Department of Medicine, Santosh Medical College, Ghaziabad, Uttar Pradesh, India
2Department of Medicine, Government Hospital, Joshimath, Uttarakhand, India
3Department of ENT, Government Hospital, Tejpur, Assam, India
4Department of Medicine, Government Hospital, Roorkee, Uttarakhand, India

Received: 16 October 2019
Accepted: 18 November 2019

*Correspondence to:
Dr. Sachin Maggo,
Email: sachinmaggo2003@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20195297

momentous burden of community-acquired pneumonia (CAP), with annual costs approximately €10.1 billion in Europe and over $17 billion in the United States. The mortality rate among outpatients is usually ≤1%, whereas among hospitalized patients the rate can range from ~12 to 40% depending upon the standard of care received.7

Risk factors for CAP include alcoholism, asthma, immunosuppression, institutionalization, and an age of ≥70 years. The spectrum of illness generally presents with fever with chills, tachycardia, cough with either non-productive or productive of mucoid, purulent, or blood-tinged sputum. If the pleura are involved, the patient may experience pleuritic chest pain. The extensive list of potential etiologic agents in CAP includes bacteria, fungi, viruses, and protozoa. Most cases of CAP, however, are caused by relatively few pathogens. The most commonly isolated CAP bacterial pathogen is Streptococcus pneumoniae. Other common causes of community-acquired bacterial pneumonia (CABP) include Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus.1 In view of the rampant rise of antibacterial resistance and limited resources in the armamentarium, novel therapies for CABP are warranted.8-12

Lefamulin (formerly known as BC-3781) is a novel, semisynthetic pleuromutilin developed for oral and intravenous administration. The drug impedes prokaryotic ribosomal protein synthesis by binding to the peptidyl transferase centre of the 50S subunit of the bacterial ribosome.13 Lefamulin selectively inhibits bacterial ribosomal translation but does not affect eukaryotic ribosomal translation. This unique mechanism of action has been associated with a low probability of cross-resistance to other antimicrobial classes based on in vitro studies.14-16 Lefamulin exhibits potent in vitro antibacterial activity against important respiratory pathogens, including Gram-positive species, such as Streptococcus pneumoniae and S. aureus (methicillin-susceptible and methicillin-resistant isolates); the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis; and the atypical pathogens Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila.17 The new drug has the advantage of being available in both oral and intravenous (IV) formulations. The US FDA in August 2019 approved Nabirva’s Lefamulin (Xenleta) for the treatment of CABP. The novel drug has proven to be a milestone in the treatment of CABP in initial results promising to cater significant unmet needs of both the physicians and the society.

MECHANISM OF ACTION

Lefamulin is a novel semi-synthetic pleuromutilin [Figure 1]. The chemical structure has a tricyclic mutilin core that is crucial for antimicrobial activity due to the interaction with the central part of the 23S rRNA through hydrophobic interactions, van der Waal forces, and hydrogen bonds.16,17 The C (14) side chain is the unique feature responsible for pharmacodynamic and antimicrobial properties of lefamulin. This side chain consists of a thioether bond, which causes increased solubility and metabolic stability, enabling the drug to be administered through both IV and PO routes.17 The C (14) side chain also helps lefamulin overcome bacterial ribosomal mutations and resistance development by maximizing the number of hydrogen bonds to the target site.18

Figure 1: Chemical structure of lefamulin (BC-3781). The tricyclic mutilin core of lefamulin consists of a C21 keto group and various C14 extensions, which are primarily responsible for the drug’s novel mechanism of 50S ribosomal protein synthesis inhibition via the A- and P-sites.16,17

Lefamulin inhibits bacterial protein synthesis by interfering with the peptidyl transferase centre by way of binding at the A- and P-site of the 50S ribosome, thereby preventing peptide bond formation.18,19 Lefamulin acts via a unique induced-fit mechanism to close the binding pocket within the ribosome, thus enabling tight binding of the drug to the target site. This is a novel mechanism for inhibiting bacterial peptide chain elongation, particularly with the first peptide bond formation, however, once elongation has started, lefamulin is ineffective. Lefamulin selectively inhibits bacterial ribosomal translation but does not affect eukaryotic ribosomal translation.20

SPECTRUM OF ACTIVITY

Gram-positive aerobes

Lefamulin demonstrates activity against all aerobic Gram-positive organisms except E. faecalis.21,22 Also, the drug is effective against resistant strains like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), heterogeneous VISA (hVISA), vancomycin-resistant S. aureus and penicillin-resistant Streptococcus pneumoniae.21,23 Lefamulin also retains susceptibility against macrolide and fluoroquinolone resistant strains of S. pneumoniae.24 Table 1 compares the minimum inhibitory concentration (MIC) ranges for lefamulin against commonly encountered Gram-positive pathogens.
**Gram-negative aerobes**

Notably, lefamulin has no activity against *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, or *Enterobacterales* due to the presence of the AcrAB-ToIC efflux pumps. However, the drug is active against fastidious Gram-negative organisms, including *H. influenzae* and *M. catarrhalis*. Table 1 compares the MIC ranges for lefamulin against commonly used Gram-negative agents.

**Anaerobic and atypical organisms**

Lefamulin has demonstrated activity against atypical organisms commonly responsible for CABP, including *Chlamydiae spp.*, *Mycoplasma spp.*, and *Legionella spp.* (Table 1). While lefamulin has some anaerobic activity, including *Clostridium perfringens*, *Cutibacterium acnes*, *Fusobacterium spp.*, *Peptostreptococcus spp.*, *Prevotella spp.*, and *Porphyromonas spp.*, it has weak activity against *Bacteroides fragilis* and does not cover *Clostridioides difficile*.21,24

**CLINICAL PHARMACOLOGY**

Pharmacokinetic and pharmacodynamic assessments are vital parts of drug development programmes for antimicrobial drugs. The pharmacokinetic profile of lefamulin has been studied in a number of pre-clinical and clinical trials. Data obtained from 12 healthy adult subjects following a single-dose of IV lefamulin 150 mg showed the time to maximum serum concentrations (tmax) was ~1 hour, with a terminal half-life (t1/2) of about 9-12 hours and a multiphasic decline.25 Supplementary studies have shown that the free plasma area under the concentration-time curve over 24 hours (FAUC0-24) was 1500.8 mg*h/l, and the free plasma maximum concentration (Cmax) was 330.1 mg/l, 22 given estimated 80-87% plasma protein binding.26,27

The pharmacokinetic properties of the PO lefamulin have also been studied. Oral lefamulin was well-tolerated, and the pharmacokinetics were similar to IV lefamulin 150 mg, but patients in the fed state had reductions in AUC0-inf (10%) and Cmax (28%).28 An additional study confirmed PO immediate-release lefamulin 600 mg to have similar pharmacokinetics to IV lefamulin 150 mg, with an absolute oral bioavailability of 25.8% in the fasted state and 21.0% in the fed state.29

Mean plasma protein binding of lefamulin ranges from 94.8% at 2.35 µg/ml to 97.1% at 0.25 µg/ml in healthy adults. The mean (min to max) steady state volume of distribution of lefamulin is 86.1 l (34.2 to 153 l) in patients with CABP after administration of the drug. Following a single IV administration of lefamulin 150 mg to healthy subjects, the highest lefamulin epithelial lining fluid (ELF) concentrations were observed at the end of infusion. The mean ELF and plasma AUC0-8 was 3.87 µg/ml and 5.27 µg/ml, respectively. The estimated ratio of ELF AUC to unbound plasma AUC is approximately 15.30

The mean (min to max) total body clearance of lefamulin is 11.9 l/h (2.94 to 30.0 l/h) in patients with CABP after IV administration of the drug. The mean (min to max) elimination half-life of lefamulin is approximately 8 hours (3 to 20 hours) in patients with CABP. Lefamulin is primarily metabolized by CYP3A4.31

Intravenous lefamulin requires dose adjustment in severe hepatic impairment (Child–Pugh Class C), specifically by extending the dosing interval. Oral lefamulin has not been studied and is therefore not recommended in those patients with moderate or severe liver impairment (Child–Pugh Classes B and C). Dosage adjustment for renal impairment, including patients on hemodialysis, is not required as lefamulin predominantly utilizes the hepatobiliary pathway for excretion (15.5% and 5.3% unchanged in urine after 150 mg IV and 600 mg oral dose, respectively).32

**DOSAGE, DRUG INTERACTIONS AND SPECIAL POPULATION**

Lefamulin can be administered either as 150 mg every 12 hour by intravenous infusion (IV) over 60 min for 5 to 7 days, or as 600 mg orally every 12 hour for 5 days.32

As described above, lefamulin is primarily metabolized by CYP3A4, strong CYP3A inducers like oral rifampin reduce the mean lefamulin AUC0-inf by 28% and 72%, when administered concomitantly with the injectable and oral formulation of the drug respectively. Likewise, CYP3A inhibitors like oral ketoconazole increase the mean lefamulin AUC0-inf by 31% and 165%, when administered concomitantly with lefamulin injection and tablets respectively.33

No clinically significant differences in the pharmacokinetics of lefamulin were observed based on age, sex, race, weight, or renal impairment including patients receiving hemodialysis. However, in patients with severe hepatic impairment (Child–Pugh Class C), intravenous lefamulin requires dose adjustment, specifically by extending the dosing interval (150 mg every 24 h). Oral lefamulin has not been studied and is therefore not recommended in those patients with moderate or severe liver impairment (Child–Pugh Classes B and C).34

**CLINICAL TRIALS**

Two phase III studies lefamulin evaluation against pneumonia (LEAP1 and LEAP2 trials) have established the safety and efficacy of lefamulin in adult patients with CABP.35,36 LEAP1 (NCT02559310) was a multicenter, double-blind randomized trial conducted in adult patients with CABP and a Pneumonia Outcomes Research Team...
Adult patients present with CABP
Enrollment into study (n=551) Randomization 1:1
≥3 days (6 doses) of IV therapy with option to switch to oral therapy based on predefined signs of improvement and investigator discretion
Moxifloxacin (± linezolid*) n=275
Follow-Up TOC 5–10 days after last dose and late follow-up 30±3 days after 1st dose
7-10 days EOT

FDA primary endpoint
Early clinical response (ECR) (Accessed 72–120 hours after first dose) Improvement in ≥2 of 4 CABP signs/symptoms, ‡ no worsening in any sign/symptom, alive, did not receive nonstudy antibacterial for CABP, ITT population, 12.5% non-inferiority margin

EMA primary endpoint
Investigator assessment of clinical response (IACR) (Accessed 5–10 days after last dose) Improvement or resolution in CABP signs or symptoms such that no additional antibacterial therapy was required to treat CABP, mITT and CE-TOC populations, 10% non-inferiority margin

Figure 2: Study design of LEAP 1 trial. LEAP1 study patients were randomized 1:1 to receive either lefamulin 150 mg IV every 12 h or moxifloxacin 400 mg IV every 24 h combined with adjunctive linezolid for any patient with suspected MRSA, with subsequent switching to oral lefamulin and oral moxifloxacin. The results of the study showed that lefamulin was safe and well-tolerated. It was found to be non-inferior to moxifloxacin in the early clinical response (ECR), namely, 96±24 hour after the first dose of the study drug in the intent-to-treat (ITT) population that was FDA’s primary endpoint (87.3% vs. 90.2%, respectively). In addition, it was non-inferior to moxifloxacin in the European Medicines Agency (EMA)’s co-primary endpoints, i.e., the investigator assessment of clinical response (IACR) 5–10 days after last dose of the study drug in the modified ITT (mITT) population (81.7% vs. 84.2%, respectively) and in the clinically evaluable (CE) population (86.9% vs. 89.4%, respectively). LEAP2 (NCT02813694) was another multicenter, randomized, double-blind study that compared the safety and efficacy of oral lefamulin (dose of 600 mg every 12 h for 5 days) with that of moxifloxacin (dose of 400 mg every 24 hour for 7 days) in patients with CABP and PORT risk class between II and IV. This study aimed to complement the results of the LEAP1 study. It was reported that lefamulin was non-inferior to moxifloxacin regardless of the PORT risk class for both FDA’s and EMA’s endpoints, i.e., for ECR in the ITT population which was the FDA’s primary endpoint (for PORT II, III, IV: 91.8%, 91.0%, and 85.0% for lefamulin; 93.1%, 90.2%, and 85.7% for moxifloxacin, respectively), and for the EMA’s co-primary endpoints of IACR in mITT population (87.5% vs. 89.1%, respectively) and in CE-test-of-cure population (89.7% vs. 93.1%, respectively).

Table 1: Summary of lefamulin susceptibility against aerobic pathogens. 15,17

<table>
<thead>
<tr>
<th>Gram positive organisms</th>
<th>Lefamulin (µg/ml)</th>
<th>Linezolid (µg/ml)</th>
<th>Vancomycin (µg/ml)</th>
<th>Daptomycin (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC$_{50}$</td>
<td>MIC$_{90}$</td>
<td>MIC$_{50}$</td>
<td>MIC$_{90}$</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> (n=5527)</td>
<td>0.12</td>
<td>0.12</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>MRSA</td>
<td>0.12</td>
<td>0.25</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Beta hemolytic <em>Streptococcus</em> (n=763)</td>
<td>0.03</td>
<td>0.03</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em>, Group A Streptococci (n=267)</td>
<td>0.03</td>
<td>0.03</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Streptococcus agalactiae</em>, Group B Streptococci (n=334)</td>
<td>0.03</td>
<td>0.03</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Viridans group <em>Streptococcus</em> (n=245)</td>
<td>0.12</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Enterococcus faecium</em> (n=536)</td>
<td>0.12</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em> (n=1473)</td>
<td>0.12</td>
<td>0.25</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Gram negative organism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> (n=360)</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em> (n=253)</td>
<td>0.12</td>
<td>0.25</td>
<td>&lt;=0.25</td>
<td>&lt;=0.25</td>
</tr>
<tr>
<td>Atypical organisms</td>
<td>Lefamulin</td>
<td>Azithromycin</td>
<td>Ceftriaxone</td>
<td>Moxifloxacin</td>
</tr>
<tr>
<td></td>
<td>Post dose increase 30-60 ms</td>
<td>12 (4.6)</td>
<td>14 (5.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Post dose increase &gt;60 ms</td>
<td>0 (0.0)</td>
<td>1 (0.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Post dose increase &gt;500 ms</td>
<td>1 (4.4)</td>
<td>1 (4.0)</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: TEAEs > 2% for study medication: safety population in LEAP 1 trial. 35,36

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Lefamulin (n=273)</th>
<th>Moxifloxacin (±linezolid) (n=273)</th>
<th>N (%)</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypokalemia</td>
<td>8 (2.9)</td>
<td>6 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>8 (2.9)</td>
<td>6 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8 (2.9)</td>
<td>5 (1.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infusion site pain</td>
<td>8 (2.9)</td>
<td>0 (0.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infusion site phlebitis</td>
<td>6 (2.2)</td>
<td>3 (1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT increase</td>
<td>5 (1.8)</td>
<td>6 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2 (0.7)</td>
<td>6 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2 (0.7)</td>
<td>21 (7.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Maximum post-dose QTc changes– day 3, n (%) in LEAP 1 trial. 35,36

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Lefamulin</th>
<th>Moxifloxacin (±linezolid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post dose increase 30-60 ms</td>
<td>12 (4.6)</td>
<td>14 (5.4)</td>
</tr>
<tr>
<td>Post dose increase &gt;60 ms</td>
<td>0 (0.0)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Post dose increase &gt;500 ms</td>
<td>1 (4.4)</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

Serious adverse events did not differ between the two groups, while the rate of discontinuation was low and similar in both groups. 39

In conclusion, lefamulin was non-inferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated.

SAFETY AND ADVERSE DRUG EFFECTS

The commonest adverse drug reactions reported from both LEAP 1 and LEAP 2 trials include injection site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and diarrhoea [Table 2]. In the LEAP 1 trial, comparable rates of adverse events were observed in both groups. Discontinuation of study drug or
withdrawal of a patient from the study due to an adverse event occurred in around 4% and 2% in the moxifloxacin and lefamulin groups, respectively. No cases of *Clostridium difficile* infection were reported in either treatment group. Diarrhoea was observed in 0.7% and 7.7% of patients receiving lefamulin and moxifloxacin (± linezolid), respectively. Low incidence of liver enzyme elevation was noted in both treatment groups consistent with CABP patient population. The rare but significant cardiovascular adverse event include changes in QT interval of potential clinical concern were also studied but found to be similar frequency between both treatment groups [Table 3].35-39

Lefamulin promises to be an alternative oral agent with established activity against new resistant organisms prevalent in the community including macrolide-resistant *M. pneumoniae* and drug-resistant *S. pneumoniae*. Also, the drug avoids fluoroquinolone antibiotics and the adverse effects associated with their use, as noted in a recent FDA boxed warning update.

Lefamulin is available in both IV and oral formulation making it as an excellent tool to be used in step down therapy (IV to oral), thereby facilitating early hospital discharge. However, further investigation of lefamulin as a first-line agent in hospitalized CABP patients is still warranted. The unique mechanism of action also ensures that the drug activity is not influenced by resistance to other antibacterial classes. However, as the drug has a favourable spectrum of activity, is safe and effective, and is available as an IV and PO formulation, the extensive utility and potential for misuse is high. Long-term studies and post marketing data will be critical in assessing the real benefits and risks of this promising compound.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**

29. Wicha WW, Lell C, Seltzer E, Prince WT, Gelone SP, Pharmacokinetics and safety of an oral, immediate-release (IR) tablet formulation of lefamulin in fed and fasted healthy subjects. 27th European Congress of Clinical Microbiology and Infectious Diseases 2017; Abstract P1336.
33. Wicha WW, Prince WT, Lell C, Heilmayer W, Gelone SP. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J


